Novartis lung cancer drug fails to meet endpoints in Phase III trial
Category: #health  By Pankaj Singh  Date: 2021-10-26
  • share
  • Twitter
  • Facebook
  • LinkedIn

Novartis lung cancer drug fails to meet endpoints in Phase III trial

Renowned pharmaceutical company, Novartis has recently disclosed that its lung cancer drug ‘canakinumab’ has failed again in meeting its goal of improving overall survival rates in lung cancer patients and preventing progression-free survival.

The Swiss-based company stated that its Canopy-1 Phase III study could not meet its primary results when patients were being treated for formerly untreated locally advanced or metastatic NSCLC (non-small cell lung cancer) combined with pembrolizumab plus platinum-based doublet chemotherapy.

The announcement serves as a setback for Novartis after the drug, combined with chemotherapy agent docetaxel, was unable to meet endpoints earlier this year to advance survival in subjects in its Canopy-2 Phase III study.

Novartis says that it would constantly inspect to determine if canakinumab would work as both an after- and pre-surgery treatment.

John Tsai, Novartis' Head of Global Drug Development and a Chief Medical Officer, said that CANOPY-1 delivers critical perceptions into the conduct of this overwhelming disease, and they will continue to investigate the data and assumptions, as well as their possible clinical implications.

Even though this trial could not offer the benefit the firm hoped for all the patients, the complete CANOPY-1 study still motivates them to support the commitment to endure studying canakinumab in lung cancer.

As of now, subject enrolment is underway in the CANOPY clinical trial programme, including a Phase III CANOPY-A trial and a Phase II CANOPY-N trial.

Basically, CANOPY-A looks at canakinumab as an adjuvant treatment after surgery, whereas CANOPY-N looks at it as a neoadjuvant treatment before surgery.

Patients that are enrolled in the CANOPY-A trial will reflect on the CANTOS study conducted on patients earlier compared to those in the CANOPY-1 trial. The CANTOS study shows that blocking the IL-1β inflammatory signal could potentially reduce the incidence and mortality of lung cancer.

Source Credit - https://health.economictimes.indiatimes.com/news/pharma/novartis-lung-cancer-drug-fails-another-phase-iii-trial/87253358

 

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Pankaj Singh    

Pankaj Singh

With an experience as an insurance underwriter and a freelance writer under his belt, Pankaj Singh boasts of quite some expertise in the field of content creation. A qualified Post Graduate in Management, Pankaj has also completed a detailed course in Digital Marketin...

Read More

More News By Pankaj Singh

Surging Covid-19 cases urge use of booster shot vaccines in Europe
Surging Covid-19 cases urge use of booster shot vaccines in Europe
By Pankaj Singh

Soaring coronavirus cases have broken past records in Europe, once again putting the continent at the epicenter of the pandemic. As a result of unprecedented events, health experts have been stressing upon the need to widen the use of booster shots ...

Vulcan Energy, Renault sign battery-grade lithium supply deal
Vulcan Energy, Renault sign battery-grade lithium supply deal
By Pankaj Singh

Australian lithium developer, Vulcan Energy has unveiled its recent partnership with French automaker Renault, SA. The move marks as the second deal over lithium supply between the two parties. The agreement comes after an anticipated surge in deman...

Volkswagen plans to double its staff in energy and charging division
Volkswagen plans to double its staff in energy and charging division
By Pankaj Singh

German automotive giant, Volkswagen has revealed plans to double its staff at its energy and charging division as well as launch a new payment technology in the coming year and form more partnerships to take on rival Tesla. VW is constantly working ...